Project Grant R01HL183440
Award Date 8/10/26
Completion Date 5/31/30
Dollars Obligated $863K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Albert Einstein College of Medicine $693,151 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the germline genetic mechanisms underlying clonal hematopoiesis of indeterminate potential (CHIP). The research will examine how noncoding germline genetic variants confer increased risk of CHIP development by influencing the expansion of mutant hematopoietic stem and progenitor cell clones. Work...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate fibrotic signatures after regenerating and non-regenerating myocardial infarction. The funded research investigates cardiac fibrosis—the deposition of extracellular matrix components in the heart following myocardial injury. While early fibrosis can be protective after myocardial...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.379 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardioprotective mechanisms of Y RNA signaling in macrophages as a potential therapeutic approach to myocardial infarction. The research dissects how a small non-coding RNA called YREX3—secreted by therapeutically-enhanced cardiac stromal cells—signals macrophages to enhance their capacity for...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $453,834 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a tissue-selective modified mRNA delivery system for cardiac injury prevention and treatment. The recipient is developing CMSMRTS 143-122, a cardiomyocyte-selective modified mRNA system encapsulated in lipid nanoparticles for intravenous administration. The system targets acid ceramidase mRNA...
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $818,022 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize endothelin-1 (ET-1) and its receptor (ET-RA) as cardiomyocyte proliferation inhibitors in neonatal mice. The research aims to identify mechanisms by which extracellular inhibitory factors suppress heart cell proliferation, with the long-term goal of enabling therapeutic strategies to...
- The National Heart, Lung, and Blood Institute awarded The Feinstein Institutes for Medical Research $586,866 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the protective role of B-1a cells in acute lung injury and to evaluate a novel therapeutic compound. The project examines the mechanisms by which B-1a cells mitigate acute lung injury and acute respiratory distress syndrome, conditions frequently triggered by sepsis or ischemia-reperfusion...
- The National Heart Lung and Blood Institute awarded the Beckman Research Institute of the City of Hope $813,810 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on nucleotide supplementation as a treatment strategy for ischemic heart disease and myocardial infarction. The project investigates the role of nucleotide balance in cardiomyocyte proliferation and aims to apply these findings for cardiac repair using large animal models....
- The National Heart, Lung, and Blood Institute awarded New York Institute of Technology $573,750 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of lysosomal membrane permeabilization in doxorubicin-induced cardiotoxicity. The research redefines understanding of how doxorubicin, a powerful cancer therapeutic, causes heart failure by focusing on lysosomal dysfunction in cardiomyocytes. Rather than emphasizing lysosomal protease release...
- The National Heart Lung and Blood Institute awarded New York University a project grant of $2,567,368 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage signaling, cell-intrinsic and cell-cell communications, and ischemic injury in diabetes through the RAGE/DIAPH1 axis. The research focuses on mitochondrial dysfunction in cardiac and skeletal muscle cells driven by RAGE ligands in diabetes and hypoxia/ischemia conditions. Project 1...